201P Afatinib for EGFR, HER2 or HER3 mutated solid tumors: A phase II Belgian precision study.
Saved in:
| Title: | 201P Afatinib for EGFR, HER2 or HER3 mutated solid tumors: A phase II Belgian precision study. |
|---|---|
| Authors: | Decoster, L.1 (AUTHOR), Aftimos, P.G.2 (AUTHOR), Rottey, S.3 (AUTHOR), Prenen, H.4 (AUTHOR), Collignon, J.J.5 (AUTHOR), Mebis, J.6 (AUTHOR), Canon, J-L.7 (AUTHOR), Fastenaekels, V.8 (AUTHOR), Cappoen, N.8 (AUTHOR), Joris, S.R.8 (AUTHOR), De Grève, J.9 (AUTHOR) |
| Source: | Annals of Oncology. 2023 Supplement 2, Vol. 34, pS262-S262. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2023.09.2924 |
